{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T13:43:16Z","timestamp":1782999796659,"version":"3.54.5"},"reference-count":21,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics and Practice"],"abstract":"<jats:p>Background: Over 30% of patients with inflammatory bowel disease (IBD) experience primary non-response to tumor necrosis factor-\u03b1 antagonists (anti-TNFs). Oncostatin M (OSM), a TNF-\u03b1-independent pro-inflammatory signaling cytokine, is emerging as a potential predictive biomarker of treatment response. Through a systematic review and meta-analysis, we assessed the utility of baseline serum or plasma OSM for predicting anti-TNF response in IBD patients. Methods: We searched PubMed, Embase, Cochrane Library, and Web of Science through March 2026 for studies reporting associations between baseline serum\/plasma OSM and endoscopic or clinical response to anti-TNF therapy in adult IBD patients. We used a bivariate random-effects model to estimate pooled sensitivity, specificity, diagnostic odds ratio (DOR), and area under the receiver operating characteristic (ROC) curve (AUC). Quality was assessed using QUADAS-2. Results: Data from four studies (n = 441 patients) were pooled. We estimated a pooled sensitivity of 82.8% (95% CI 71.4\u201390.3%) and a specificity of 88.4% (95% CI 82.7\u201392.4%) for predicting anti-TNF non-response. The pooled AUC was 0.899 (95% CI 0.858\u20130.940), with low heterogeneity (I2 = 16.0%). The pooled DOR was 36.7 (95% CI 15.7\u201385.8), with a positive likelihood ratio of 7.1 and a negative likelihood ratio of 0.19. Risk of bias was low across the studies. Conclusions: Higher serum OSM was associated with treatment failure in IBD patients receiving anti-TNF therapy, with a pooled AUC of 0.899 in assay-stratified analysis and 0.820 when all studies were included. However, the small number of available studies, substantial variability in OSM cutoffs (14\u2013233.6 pg\/mL) and assay heterogeneity limit the robustness and generalizability and call for additional prospective data to more-robustly characterize the clinical utility of OSM.<\/jats:p>","DOI":"10.3390\/clinpract16070124","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T10:04:44Z","timestamp":1782986684000},"page":"124","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum or Plasma Oncostatin M for Predicting Primary Non-Response to Tumor Necrosis Factor-\u03b1 Antagonist Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"16","author":[{"given":"Maxwell A.","family":"Barffour","sequence":"first","affiliation":[{"name":"Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Karanja","sequence":"additional","affiliation":[{"name":"College of Medicine, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Missouri School of Medicine, Columbia, MO 65201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan S.","family":"Kais","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Cincinnati, Cincinnati, OH 45221, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Kapur","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Motility, University of Kansas School of Medicine, Kansas City, KS 64110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yezaz A.","family":"Ghouri","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, St. Louis University School of Medicine, St. Louis, MO 63110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17562848211059954","DOI":"10.1177\/17562848211059954","article-title":"Tumour necrosis factor inhibitors in inflammatory bowel disease: The story continues","volume":"14","author":"Sandborn","year":"2021","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Atreya, R., Neurath, M.F., and Siegmund, B. (2020). Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?. Front. Med., 7.","DOI":"10.3389\/fmed.2020.00517"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.3748\/wjg.v29.i29.4481","article-title":"Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review","volume":"29","author":"Wang","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Chen, P., Zhou, G., Lin, J., Li, L., Zeng, Z., Chen, M., and Zhang, S. (2020). Serum Biomarkers for Inflammatory Bowel Disease. Front. Med., 7.","DOI":"10.3389\/fmed.2020.00123"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000527846","article-title":"Positioning and Usefulness of Biomarkers in Inflammatory Bowel Disease","volume":"104","author":"Sakurai","year":"2023","journal-title":"Digestion"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nm.4307","article-title":"Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease","volume":"23","author":"West","year":"2017","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ebiom.2019.01.027","article-title":"Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease","volume":"40","author":"Verstockt","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.dld.2022.03.008","article-title":"Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab","volume":"54","author":"Bertani","year":"2022","journal-title":"Dig. Liver Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/apt.15870","article-title":"Serum oncostatin M at baseline predicts mucosal healing in Crohn\u2019s disease patients treated with infliximab","volume":"52","author":"Bertani","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.clinbiochem.2021.11.011","article-title":"Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease measured by chemiluminescence immunoassay","volume":"100","author":"Cao","year":"2022","journal-title":"Clin. Biochem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41598-022-05208-9","article-title":"High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor \u03b1 antagonists","volume":"12","author":"Guo","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1093\/ibd\/izab032","article-title":"Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease","volume":"27","author":"Verstockt","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/jama.2017.19163","article-title":"Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement","volume":"319","author":"McInnes","year":"2018","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jclinepi.2005.02.022","article-title":"Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews","volume":"58","author":"Reitsma","year":"2005","journal-title":"J. Clin. Epidemiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jclinepi.2005.01.016","article-title":"The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed","volume":"58","author":"Deeks","year":"2005","journal-title":"J. Clin. Epidemiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/gutjnl-2017-315494","article-title":"Cell-centred meta-analysis reveals baseline predictors of anti-TNF\u03b1 non-response in biopsy and blood of patients with IBD","volume":"68","author":"Gaujoux","year":"2019","journal-title":"Gut"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1056\/NEJMra1907607","article-title":"Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease","volume":"385","author":"Baumgart","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/ecco-jcc\/jjz195","article-title":"Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice","volume":"14","author":"Gisbert","year":"2020","journal-title":"J. Crohns Colitis"}],"container-title":["Clinics and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2039-7283\/16\/7\/124\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:46:25Z","timestamp":1782996385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2039-7283\/16\/7\/124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["clinpract16070124"],"URL":"https:\/\/doi.org\/10.3390\/clinpract16070124","relation":{},"ISSN":["2039-7283"],"issn-type":[{"value":"2039-7283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]}}}